Back
Yubo International Biotech 10K Form
Sell
46
YBGJ
Yubo International Biotech
Last Price:
$0.1100
Seasonality Move:
141.73%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2021-05-24 | 10Q | YBGJ/Yubo International Biotech Quarterly |
| 2021-04-23 | 10K | YBGJ/Yubo International Biotech Annual |
| 2021-01-19 | 10Q | YBGJ/Yubo International Biotech Quarterly |
| 2020-10-20 | 10Q | YBGJ/Yubo International Biotech Quarterly |
| 2020-07-20 | 10Q | YBGJ/Yubo International Biotech Quarterly |
| 2020-06-25 | 10K | YBGJ/Yubo International Biotech Annual |
Receive YBGJ News And Ratings
See the #1 stock for the next 7 days that we like better than YBGJ
YBGJ Financial Statistics
Sales & Book Value
| Annual Sales: | $3.5K |
|---|---|
| Cash Flow: | $-398.2K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $-0.03 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -0.02440 |
|---|---|
| Net Income (TTM): | $-1.8M |
| Gross Margin: | $2.7K |
| Return on Equity: | 0% |
| Return on Assets: | -70.03% |
Yubo International Biotech Earnings Forecast
Key Yubo International Biotech Financial Ratios
-
The Gross Profit Margin over the past 20 years for YBGJ is 76.37%.
-
The Selling, General & Administrative Expenses for YBGJ have been equal to 35,951.30% of Gross Profit Margin.
-
The Net Earning history of YBGJ is -51,161.38% of Total Revenues.
-
Per Share Earnings over the last 25 years have been positive in 8 years.
Yubo International Biotech Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | OTCM |
|---|---|
| Current Symbol: | YBGJ |
| Website: | yubogroup.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0.21 |
| Quick Ratio: | 0.13 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
YBGJ Technical Analysis vs Fundamental Analysis
Sell
46
Yubo International Biotech (YBGJ)
is a Sell
Is Yubo International Biotech a Buy or a Sell?
-
Yubo International Biotech stock is rated a SellThe current Yubo International Biotech [YBGJ] share price is $0.1120. The Score for YBGJ is 46, which is 8% below its historic median score of 50, and infers higher risk than normal.